WG
KRYS icon

Winton Group’s Krystal Biotech KRYS Stock Holding History

Winton Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,874
Closed -$1.45M – 1267
2025
Q4 		$1.45M Sell
5,874
-2,338
-28% -$492K 0.05% 348
2025
Q3 		$1.45M Buy
+8,212
New +$1.23M 0.05% 310
2025
Q2 		– Sell
-7,274
Closed -$1.31M – 914
2025
Q1 		$1.31M Buy
7,274
+709
+11% +$119K 0.08% 243
2024
Q4 		$1.03M Buy
6,565
+1,274
+24% +$226K 0.07% 351
2024
Q3 		$963K Buy
5,291
+330
+7% +$63.6K 0.07% 334
2024
Q2 		$911K Buy
+4,961
New +$833K 0.06% 313

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Winton Group's KRYS Position: Q1 2026 in Review

Winton Group sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 5,874 shares — an estimated $1.45M sold.

Winton Group first reported a position in KRYS in Q2 2024 and held it in 6 quarters. The position peaked at $1.45M in Q3 2025. 368 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Winton Group reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 5,874 Krystal Biotech shares in Q1 2026, an estimated $1.45M.
  • Winton Group first reported a position in Krystal Biotech in Q2 2024 and held it in 6 quarters.
  • Winton Group's Krystal Biotech position peaked at $1.45M in Q3 2025.
  • 368 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.